Interest in Evaluating Primary Hemostasis in Patients With Veno-venous Extracorporeal Membrane Oxygenation (ECMO)

Patients With ECMO Clinical Trial

— ECMO PFA-100  

Official title:

Interest in Evaluating Primary Hemostasis in Patients With Veno-venous Extracorporeal Membrane Oxygenation (ECMO)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03248596
• Other study ID #: 35RC15_3023_ECMO PFA-100
• Status: Terminated
• Phase: N/A
• First received: August 9, 2017
• Last updated: November 17, 2017
• Start date: February 2016
• Est. completion date: July 2016

Study information

• Verified date: November 2017
• Source: Rennes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the study is a better understanding of hemorrhagic events causes in patients with ECMO, prevent them and decrease the number of transfusion.

Description:

The most frequent complication during ECMO is hemorrhage especially as a curative anticoagulant treatment is necessary. The primary hemostasis is also affected with a von Willebrand disease and thrombopathy, well known but not studied by recent tests.The identification of primary haemostasis deficits with these tools would allow to supply them and decrease the morbi-mortality related to the transfusion.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient older than 18 years old

• Patient with ECMO

• Patient hospitalized in an intensive care unit at the University Hospital of Rennes

Exclusion Criteria:

• Known history for constitutional pathology of the primary haemostasis

• Platelets < 100000 / mm3 or hematocrit < 28 % between H+12 and H+24

Related Conditions & MeSH terms

• Patients With ECMO

Locations

Country	Name	City	State
France	CHU de Rennes	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate primary hemostasis in patient with ECMO at University Hospital of Rennes		Day 5